Analysts have raised their price target for Neogen from $6.50 to $7.67, citing a slightly lower discount rate and forward profit expectations. Revenue growth projections remain stable.
What's in the News
- Renewed partnership with the United States Equestrian Federation to expand educational initiatives and prevention protocols for equine botulism, with continued promotion of the BotVax B vaccine. (Key Developments)
- Chief Financial Officer David Naemura announced his resignation and will assist with onboarding a successor. The decision was not the result of disagreements over company policies or procedures. (Key Developments)
- Entered collaboration with Biomatter to develop new AI-enabled enzyme products for food safety applications using Biomatter's Intelligent Architecture platform. (Key Developments)
- Reported a goodwill impairment charge of $597.9 million for the three months ended May 31, 2025. (Key Developments)
- Launched Molecular Detection Assay: Listeria Right Now, a rapid on-site tool aimed at improving environmental Listeria detection in food safety. (Key Developments)
Valuation Changes
- Consensus Analyst Price Target has risen from $6.50 to $7.67.
- Discount Rate has fallen slightly from 9.14% to 8.95%.
- Revenue Growth forecast remains stable at approximately negative 1.34%.
- Net Profit Margin is marginally lower, moving from 12.49% to 12.32%.
- Future P/E has increased from 17.17x to 20.41x.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.